Hangzhou Jeci Biochemical Technology Co., Ltd. is a physical and chemical enterprise mainly based on pharmaceutical and chemical industry. The company has been established for a long time. It is located in Shangcheng District, a feng shui treasure land in Hangzhou, Zhejiang Province. It is beautiful and rich, with outstanding people, convenient transportation and economic development.
Our company's various chemical qualifications and certificates are complete, there are a variety of pharmaceutical intermediates and precursor chemicals, and most of the common dangerous goods business qualifications, and have complete import and export qualifications, the company's products are sold all over the world, and Acting for the import and export of various products such as hazardous chemicals.
The company is mainly engaged in wholesale, retail, biological products, pharmaceutical intermediates, first-class medical equipment, petroleum products, rubber products, plastic products, biological reagents, biochemical testing reagents and consumables, chemical reagents; pharmaceutical operations (operating with valid licenses) Import and export of goods and technology (except for projects prohibited by national laws and administrative regulations, and laws and administrative regulations stipulate that projects that restrict operations can only be operated after obtaining a permit). (Projects subject to approval according to law may be operated after approval by relevant departments)
In China, we have a strong collaborative R&D team, working in depth with new drug research institutes and multiple custom processing plants. We have very good domestic sales channels and have long-term relationships with domestic companies, including product applications, technology transfer, product supply, custom processing, and exclusive agents for multiple products in multiple regions. In addition, we also provide factory quality management system certification consulting services.
Internationally, we have long-term trade relations with India, Southeast Asia, South Korea, Japan and other markets, and provides products in the whole process of market and sales services. At the same time, we also provide product registration, consulting and sales channel expansion services for overseas companies in the Chinese market.
In China, we have a strong collaborative R&D team, working in depth with new drug research institutes and multiple custom processing plants. We have very good domestic sales channels and have long-term relationships with domestic companies, including product applications, technology transfer, product supply, custom processing, and exclusive agents for multiple products in multiple regions. In addition, we also provide factory quality management system certification consulting services.
Internationally, we have long-term trade relations with India, Southeast Asia, South Korea, Japan and other markets, and provides products in the whole process of market and sales services. At the same time, we also provide product registration, consulting and sales channel expansion services for overseas companies in the Chinese market.
ADCs have become one of the most promising therapeutic strategies in the current innovative drug field.
At this year's J.P. Morgan Healthcare Conference, several multinational corporations (MNCs) explicitly included ADCs as a core technology platform in their R&D planning-whether for monotherapy or combination therapy, the weight of ADCs in oncology pipelines continues to increase, making them a central focus of these industry giants.
However, the potential of ADCs extends far beyond oncology. From a treatment logic perspective, the "precise targeting + potent killing" characteristics of ADCs align well with the core needs of autoimmune diseases: "precise intervention and long-term control."
In fact, exploration of autoimmune ADCs has long been underway. As a global leader in the autoimmune field, AbbVie was the first to take steps in this direction. Unfortunately, its two autoimmune ADC candidates, ABBV-3373 and ABBV-154, were terminated due to issues such as insufficient druggability and risks associated with glucocorticoid exposure, leaving both experience and challenges for the field.
Yet the setbacks of early pioneers have not halted exploration. Today, Chinese biopharmaceutical companies have evolved from followers to key participants in the emerging autoimmune ADC space. Multiple domestic firms, including InnoCare Pharma, Hengrui Medicine, and Simcere Pharmaceutical, have already developed multiple autoimmune ADC pipelines and advanced them into clinical stages.
Although precision treatment of autoimmune diseases driven by ADCs is still in the early exploratory phase, and its clinical value and mechanism of action still require more definitive data, it is undeniable that a new round of innovation competition around autoimmune ADCs has quietly begun.
01 Next-Generation Autoimmune Drugs
The search for drugs to treat autoimmune diseases never stops.
Over the past two decades, treatment for some autoimmune conditions has seen leapfrog progress. From first-line therapies primarily based on corticosteroids and traditional immunosuppressants, to the continuous validation of targets such as TNF, IL-6, IL-17, BAFF, and CD20, treatment has moved toward greater precision, with significantly improved control of disease activity in patients.
However, there remains substantial room for improvement. On one hand, only a small number of diseases have achieved truly precise treatment; on the other, even precise treatments face a series of issues related to efficacy, compliance, and safety.
Therefore, there are still unmet needs in the autoimmune field. More precise and sustainably manageable immune modulation is the goal of "next-generation" autoimmune drugs, and ADCs show particular promise in this context.
Unlike oncology, where the emphasis is on "cell clearance," the core of autoimmune ADCs lies in targeting specific phenotypes of immune cells (such as autoreactive B cells or T cells), delivering payloads precisely to pathogenic immune cells, thereby suppressing inflammatory responses while preserving overall immune function.
This high degree of targeting and functional removal means that autoimmune ADCs can offer higher efficacy and lower systemic toxicity.
More importantly, autoimmune diseases require not only "fast onset" but also long-term control. In chronic autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, excessive and persistent immune activation is a defining feature.
ADCs inherit the pharmacokinetic advantages of their antibody components, especially their long plasma half-lives, which allow for lower dosing frequency compared to traditional small-molecule drugs-enabling weekly or biweekly administration. Additionally, the targeted nature of ADCs means that required doses are lower than those for systemic treatments, while still maintaining stable disease control.
For these reasons, the successful transition of ADCs from oncology to autoimmunity lies in their targeting ability, delivery efficiency, and safety profile, which directly address long-standing pain points of traditional autoimmune drugs.
02 Pioneer AbbVie
Practice has already begun.
After the patent cliff for Humira (adalimumab), Skyrizi and Rinvoq quickly filled the sales growth gap for AbbVie in the autoimmune sector, confirming its "dominance" in this field.
Even before tumor ADCs fully exploded, AbbVie-one of the earliest MNCs to invest in ADC technology-had attempted to introduce ADCs into immunoinflammatory diseases. ABBV-3373 and ABBV-154 were two key projects in this direction.
Among them, ABBV-3373 used adalimumab as the antibody backbone, conjugated with a glucocorticoid receptor modulator as the payload, aiming to deliver anti-inflammatory effects directly to activated immune cells.
Early clinical trials showed impressive efficacy signals: in a Phase II study comparing ABBV-3373 head-to-head with adalimumab in moderate-to-severe rheumatoid arthritis, at week 12, the DAS28-CRP score reduction was significantly greater in the ABBV-3373 group (-2.65 vs -2.29; p=0.022).
Notably, among 17 patients who achieved low disease activity at week 12, 70.6% maintained this status at week 24 after discontinuation-a result once regarded as key evidence that autoimmune ADCs could achieve sustained deep remission.
However, problems soon emerged. Because the payload was steroid-based, long-term exposure risk persisted. Four adverse events were reported in the ABBV-3373 treatment group, including one case of anaphylactic shock.
ABBV-154 faced similar challenges. It was an optimized version of ABBV-3373, with improvements to linker and payload design to enhance druggability.
Although ABBV-154 achieved statistically significant improvements across all primary efficacy endpoints in a Phase II trial for polymyalgia rheumatica, two tumor events occurred during the study and were assessed as possibly drug-related. Compared with competitors, its benefit-risk ratio was deemed insufficient, leading AbbVie to terminate development.
Nevertheless, AbbVie's withdrawal did not end this technological pathway; instead, it sent a critical signal to the industry: the efficacy rationale for autoimmune ADCs is valid and holds promise for sustained deep remission.
03 Differentiation Competition Begins
Today, autoimmune ADCs are gaining momentum. Although still in early stages, "differentiation" competition has already started in terms of target selection, formulation, and indication choice.
In target selection, B cells, T cells, and molecules related to their activation pathways remain key focuses for autoimmune ADCs. Antibody targets such as BCMA, CD19, and CD20 are being re-explored for ADC applications, while ADCs targeting IL-7R, IL-6, CD45, etc., have completed animal model validation, covering indications such as arthritis, transplant conditioning, and scleroderma.
Lifordi represents another approach: its autoimmune ADC LFD-200 targets VISTA, a cell surface protein specifically expressed on immune cells. Upon antibody binding, it rapidly internalizes and accumulates intracellularly, facilitating efficient payload entry into target cells while reducing off-target toxicity.
Preclinical data disclosed at ACR 2025 showed that LFD-200, when dosed continuously for 13 weeks, maintained glucocorticoid exposure within immune cells without observed systemic toxicity. This result helped the company secure a $42 million strategic investment from Sanofi Ventures.
In this round of autoimmune ADC development, Chinese biopharmaceutical companies are taking the lead.
InnoCare Pharma has developed DB-2304, an autoimmune ADC targeting BDCA2, based on its DIMAC platform. Data presented at AIC2025 showed that in healthy subjects, a dose of 1 mg/kg every four weeks maintained over 95% BDCA2 receptor occupancy. Its Phase II study for SLE has completed the first patient dosing.
Meanwhile, domestic companies are innovating formulations to open new possibilities: Hengrui's SHR4597 is an inhaled IL-4R ADC for asthma treatment, using local administration to further reduce systemic exposure. The Phase II study started in April 2025, but recruitment has not yet begun.
Another IL-4R ADC, BR2060 by BioRay, filed for clinical trials in January 2026 and was accepted by the CDE, becoming the second IL-4R ADC to enter clinical stage after SHR-4597. Simcere's SIM0708 is currently in preclinical development.
Additionally, some mature oncology ADCs are "crossing over" into autoimmunity: Brentuximab Vedotin, a CD30 ADC for Hodgkin lymphoma, has initiated feasibility clinical trials for early-stage diffuse cutaneous sclerosis.
Although autoimmune ADCs have yet to reach approval, early clinical efficacy suggests hope for long-term treatment, awaiting major breakthroughs.
